Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nemes

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 11, 2007
Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia AL Nemes, T Lissitchkov, A Klukowska, et al.
Acta Haematologica|February 29, 2008
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III studyL Nemes, T Lissitchkov, G Dobaczewski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 30, 2012
Haemophilia care in Europe: the ESCHQoL studyW Schramm, A Gringeri, R Ljung, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V LeidenI Pabinger, L Nemes, C Rintelen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 29, 2017
PK-guided personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rhFVIII) in adults with severe haemophilia AT Lissitchkov, L Rusen, P Georgiev, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophiliaR A Gruppo, D Malan, J Kapocsi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 29, 2009
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIIIM Recht, L Nemes, M Matysiak, et al.
Journal of Thrombosis and Haemostasis : JTH|March 3, 2011
Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease populationA Mohl, Z Boda, R Jager, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 11, 2007
Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia AL Nemes, T Lissitchkov, A Klukowska, et al.
Acta Haematologica|February 29, 2008
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III studyL Nemes, T Lissitchkov, G Dobaczewski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 30, 2012
Haemophilia care in Europe: the ESCHQoL studyW Schramm, A Gringeri, R Ljung, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V LeidenI Pabinger, L Nemes, C Rintelen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 29, 2017
PK-guided personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rhFVIII) in adults with severe haemophilia AT Lissitchkov, L Rusen, P Georgiev, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophiliaR A Gruppo, D Malan, J Kapocsi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 29, 2009
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIIIM Recht, L Nemes, M Matysiak, et al.
Journal of Thrombosis and Haemostasis : JTH|March 3, 2011
Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease populationA Mohl, Z Boda, R Jager, et al.
Pageof 4